CSB-MP006254HU(F1)is detected by Mouse anti-6*His monoclonal antibody. Excellent Bioactivity Validated by Functional ELISA Immobilized Human CXCR4 at 10 μg/ml can bind Anti-CXCR4 recombinant antibody (CSB-RA00
The CXCR4鈥 CXCL12 axis is now targeted in a first, ongoing clinical trial in CLL patients who are treated with plerixafor in combination with the anti-CD20 antibody rituximab. The fact that CLL cells express high levels of CXCR4 and readily respond to CXCL12 , along with easy access to ...
antibody, DC101 (Kioi et al., 2010). These results are bolstered by the favorable safety profile of AMD3100 in humans (Hendrix et al., 2000), and there is an early-stage clinical trial examining AMD3100 (also known as plerixafor) either alone or in combination with bevacizumab to treat...
In CT-2A glioma-bearing mice, treatment with anti-VEGF antibody B20-4.1.1 alone significantly reduced the tumor volume compared with controls (by 57%, P < 0.01) or POL5551 alone (by 62%, P < 0.01). The combination of POL5551 with B20-4.1.1 did not decrease the tumor volume further...
A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clin Cancer Res. 2020;26:344–53. Article PubMed CAS Google Scholar Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, ...
After washing with PBS for 3 times, the sample was immersed with the appropriate secondary antibody (1:500, Jackson Immunoresearch) for 1.5 h. The tissue slices and cell slides were washed twice in PBS and then incubated in DAPI for 30 min. The sample were sealed with neutral resin after ...
The anti-CXCR7 monoclonal antibody CXCR7/RDC-1 (Clone 11G8) and anti-CXCR4 monoclonal antibody human CXCR4 (Clone 12G5) were from R&D Systems (Minneapolis, MN, USA). Cytotoxicity assay Cells were plated in 96-well plates (1500 cells/well) and 3-day cytotoxicity assays were performed ...
After washing, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (1:5000) at RT for 2 h, and then visualized with a chemiluminescence substrate. Scratch wound healing assay. BMSCs were seeded in 6-well plates, and the cells were serum starved for 12...
clinical applicability so far. Unfortunately, the pronounced sensitivity of the Pentixafor scaffold towards even minor structural modifications [82], that ultimately lead to strongly decreased CXCR4 affinity, precludes the use of its177Lu- or90Y-labeled version as the corresponding CXCR4-targeted ...
Furthermore, the similar levels of cell death observed in CLL-B cells cultured in presence or absence of stromal cell support suggest that the CXCR4 antibody has the potential to overcome the protection provided by the microenvironment. These findings may have significant clinical implications in ...